Interobserver agreement for the detection of optical coherence tomography features of neovascular age-related macular degeneration.

PURPOSE To investigate the interobserver agreement for the detection of optical coherence tomography (OCT) features of disease activity in patients with neovascular age-related macular degeneration (nAMD). METHODS This was a cross-sectional agreement study in which grading of OCT line scans from patients with nAMD was conducted by two retinal specialists before the patients received treatment. Scans were graded for the presence of features of nAMD disease activity (intraretinal cysts [IRC], subretinal fluid [SRF], diffuse retinal edema [DRE], retinal pigment epithelial detachment [PED], and subretinal tissue [SRT]). RESULTS Although scans from 78 patients were available for analysis, five patients were excluded because of a mean signal strength of <7. Two hundred seventy-eight line scans were analyzed from 73 patients (40 with cross-hair scan sets and 33 with radial line scan sets). Agreement for per line scan analysis was 77% for IRC (kappa = 0.41), 81% for SRF (kappa = 0.62), 91% for macular fluid (kappa = 0.28), 79% for DRE (kappa = 0.10), 90% for PED (kappa = 0.78), and 79% for SRT (kappa = 0.53). Both observers disagreed regarding the presence of macular fluid in one patient (with a cross-hair scan). CONCLUSIONS Interpretation of OCT line scans from patients with nAMD is subject to interobserver variability. However, when all line scans acquired are examined for the presence of fluid (IRC or SRF), there is a high level of agreement for the detection of macular fluid on a per patient basis.

[1]  J. R. Landis,et al.  The measurement of observer agreement for categorical data. , 1977, Biometrics.

[2]  C. Toth,et al.  Optical coherence tomography reader agreement in neovascular age-related macular degeneration. , 2007, American journal of ophthalmology.

[3]  William J Feuer,et al.  An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. , 2007, American journal of ophthalmology.

[4]  C. Lantz,et al.  Behavior and interpretation of the κ statistic: Resolution of the two paradoxes , 1996 .

[5]  C. Regillo,et al.  Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients. , 2007, American journal of ophthalmology.

[6]  L. da Cruz,et al.  Repeatability of stratus optical coherence tomography measures in neovascular age-related macular degeneration. , 2008, Investigative ophthalmology & visual science.

[7]  Gerald Liew,et al.  Ranibizumab for neovascular age-related macular degeneration. , 2007, The New England journal of medicine.

[8]  Maciej Wojtkowski,et al.  Ophthalmic imaging by spectral optical coherence tomography. , 2004, American journal of ophthalmology.

[9]  Susan Schneider,et al.  Ranibizumab versus verteporfin for neovascular age-related macular degeneration. , 2006, The New England journal of medicine.

[10]  C. Lantz,et al.  Behavior and interpretation of the kappa statistic: resolution of the two paradoxes. , 1996, Journal of clinical epidemiology.

[11]  A. Viera,et al.  Understanding interobserver agreement: the kappa statistic. , 2005, Family medicine.

[12]  C. Bunce,et al.  A randomised, double-masked phase III/IV study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularisation secondary to age-related macular degeneration: clinical trial design , 2008, Trials.